Luis E. Raez/X
Aug 1, 2025, 16:21
Luis Raez: 3 INDs Approved for Patients with HER2 Mutations and Lung Cancer
Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute, shared a post on X:
“I want to give thanks to the FDA, at Memorial Cancer Institute we got today 3 INDs approved at the same time for patients with HER2 mutations and lung cancer to start zongertinib! If we can continue working this way we can benefit a lot of patients.”
More posts featuring Luis E. Raez.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32